Hepatitis B Therapeutics Market

Market Overview

The Global Hepatitis B Therapeutics market size was valued at USD 4.03 billion in 2022. It is projected to reach USD 5.57 billion by 2031, growing at a CAGR of 3.65% during the forecast period (2023–2031). 

The hepatitis B virus can produce a severe liver infection, which can be fatal. It's a significant issue worldwide since it can lead to long-term infections and significantly increase the danger of developing cirrhosis or cancer of the liver. Market growth could be hampered by factors such as intense rivalry, difficulties in management, a shortage of diagnostic tools, prohibitive healthcare costs, and government oversight. Increases in biomarker-based testing, collaboration, innovation, and research; HBV therapies in development; government activities and public awareness are just a few possible outcomes.

Market Dynamics

Market Drivers

Growing Incidence of Hepatitis B

Cases of hepatitis infection are rising due to the widespread use of alcohol and illicit drugs and poor sanitation conditions. Thus, it is expected that the market for hepatitis treatments will expand at a significantly high rate due to these causes. A significant driver of the hepatitis treatment market is the increasing recognition of the need to eradicate the virus in many nations and international organizations. Nearly 325 million people are infected with hepatitis at any given time, according to data from the World Health Organization (WHO). This data demonstrates the alarming rise in hepatitis infection rates around the globe.

Market Restraint

High Cost of Medical Care

Chronic infection with the hepatitis B virus (HBV) is one of the world's most pressing public health issues. Because symptoms typically don't appear until at least six months following HBV exposure, the condition is sometimes called a "silent illness." It is essential to incorporate drug resistance and laboratory testing expenses when estimating the total cost of treating chronic hepatitis B. Although avoidable and curable, Hepatitis B nevertheless claims the lives of about a million people every year. Only antivirals are effective against HBV, and there aren't too many on the market. The price of medical care and prescription drugs is prohibitive for many people.

Market Opportunities

Growth in Pharmaceutical Research and Development

Business enterprises spend money on research and development (R&D) initiatives to create cutting-edge innovations. Market researchers predict that this will help the hepatitis therapies industry expand. Players are also merging, acquiring, forming joint ventures, and forming alliances to further their expansion efforts. Collectively, these factors contribute to a faster expansion of the hepatitis treatment industry. Several nations have made it a priority to strengthen their healthcare systems to serve their inhabitants better. The market for hepatitis treatments is expected to expand on the back of favorable reimbursement policies adopted by government bodies in several nations.

Regional Analysis

The global hepatitis B therapeutics market is bifurcated into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.

North America Dominates the Global Market

North America is the most significant shareholder in the global market and is expected to grow during the forecast period. The hepatitis therapeutics market in the United States is expected to grow due to rising hepatitis incidence and mortality rates and increasing spending on hepatitis medications. The United States is a crucial market because of the country's huge demand, its relatively well-off patient population, and its familiarity with cutting-edge treatments. Some of the most important variables contributing to the high share include sophisticated healthcare infrastructure, the availability of reimbursement, and access to the latest and most innovative treatments. Growth in the United States market is driven by several factors, including significant industry competitors, the expansion of regional awareness programs, and the introduction of cutting-edge goods to the market.

Europe is expected to grow during the forecast period. During the projected period, the market in Eastern Europe is expected to develop due to the region's favorable fundamentals, high viraemic prevalence, and rising demand for hepatitis medications for early treatment of the condition. Growth in the market is fueled by factors such as the rising prevalence of hepatitis B due to a lack of antibiotics and the efficacy of antivirals against Hepatitis B infections. Additionally, Hepatitis B drugs and treatments are quite costly. Therefore rising levels of disposable income are fueling market expansion.

Growth prospects in the region are bolstered by several factors, including a high illness burden, increasing access to medicines, improved healthcare and sanitation, and more awareness about hepatitis immunization. Countries like India, China, Indonesia, and others in the South Asian economic region are constantly growing their healthcare expenditure and reimbursement coverage to ensure more people have access to high-quality medical treatment. In addition, the Asia-Pacific area is expected to benefit from the rising demand for generic pharmaceuticals. More than half of the world's HCV-infected population resides in the nations included in this agreement. During the patent period for these HCV drugs, generic versions of these drugs are expected to be released by several manufacturers thanks to licenses negotiated by the Medicine Patent Pool. It is expected to significantly impact the market, with prices for these drugs decreasing and consumption rates rising over the forecast period.

Due to the relatively underdeveloped market for hepatitis B medicines in Latin America, expansion in the region is anticipated to be stable. A rising number of people are becoming educated about hepatitis B, which is a factor that bodes well for the development of the market in the region. In all countries except Brazil and the Dominican Republic, the seroprevalence of anti-HBc was the same in both sexes. Manufacturers are increasing their operations in the Middle East and Africa (MEA) and Latin America (LA) regions to meet the significant unmet demands for improved treatment as the patient population in the United States and other developed areas decreases due to the beneficial effects of employing HCV medicines.

Segmental Analysis

The global hepatitis B therapeutics market is segmented by therapy, product type, and distribution channel.

By Therapy Analysis

Based on therapy, the global market is bifurcated into chemotherapy, immunosuppressant therapy, and nucleoside analogue.

The nucleoside analogue segment is the highest contributor to the market and is expected to grow during the forecast period. An increasingly significant of antiviral medication sand nucleoside analogue are used to treat infections caused by viruses like HIV, hepatitis B and C, cytomegalovirus, herpes simplex virus, and varicella-zoster virus. The analogue of nucleosides mimics the action of natural nucleosides by halting the growth of a new DNA strand. DNA replication requires these chemicals, but only the viral polymerases require them. Therefore they are generally harmless and well tolerated. Nucleoside analogue are a broad category of pharmaceuticals that include anticancer medications. Sometimes referred to as reverse transcriptase inhibitors, nucleoside analogs are used to treat HIV infection.

By Product Type Analysis

Based on product type, the global market is bifurcated into hepatitis B vaccine and anti-viral drugs.

The hepatitis B vaccine segment is the highest contributor to the market and is expected to grow during the forecast period. The hepatitis B virus can produce a severe liver illness (HBV). It's an international crisis that affects people's health everywhere. It raises the chance of dying from cirrhosis and liver cancer and can lead to a persistent infection. The hepatitis B vaccine is secure and effective, offering 98% to 100% protection. By avoiding contracting hepatitis B, you can spare yourself from health problems like chronic disease and liver cancer. Vaccinating newborns against hepatitis B at birth is a crucial step toward stopping the spread of the disease and protecting infants from developing chronic health problems.

By Distribution Channel Analysis

Based on distribution channel, the global market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies.

The retail pharmacies segment is the highest contributor to the market and is expected to grow during the forecast period. Pharmacy professionals have an opportunity to help lessen the effects of viral hepatitis. Although there may be some debate about providing access to clean syringes among pharmacists, doing so is one of the best things you can do to fight against hepatitis. The prevalence of viral hepatitis in the United States is a significant health problem, and pharmacists can help. Pharmacists are uniquely positioned to raise patients' awareness of, prevent, and access treatment for these severe diseases by administering vaccinations and counseling on prevention, testing, and treatment.

Recent Developments

• November 2022- Johnson & Johnson, the largest and most diversified healthcare company in the world, and Abiomed, the global leader in innovative heart, lung, and kidney support technologies, have announced that they have entered into an authoritative agreement for Johnson & Johnson to tender offer for and acquire Abiomed.
• June 2022- Roche introduces a unique dual antigen and antibody diagnostic test to aid in the fight to eradicate the hepatitis C virus.